PIK3CA and ESR1 mutations detected in circulating tumor DNA (ctDNA) are predictive factors for late-line hormone-based therapies in ER+/HER2-metastatic breast cancer (MBC)

被引：0

作者：

Chen, Tom Wei-Wu ^{[1
]}

Dai, Ming-Shen ^{[2
]}

Chang, Dwang-Ying ^{[1
]}

Lin, Ching-Hung ^{[3
]}

Chen, I-Chun ^{[3
]}

Wang, Ming-Yang ^{[1
]}

Huang, Ling-Yi ^{[4
]}

Hsu, An ^{[4
]}

Zhuo, De-Wei ^{[4
]}

Tan, Kien Thiam ^{[4
]}

Lu, Yen-Jung ^{[4
]}

Chang, Shu-Han ^{[1
]}

Cheng, Ann-Lii ^{[3
]}

Lu, Yen-Shen ^{[1
]}

机构：

[1] Natl Taiwan Univ Hosp, Taipei, Taiwan

[2] Triserv Gen Hosp, Taipei, Taiwan

[3] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan

[4] ACT Genom Co Ltd, Taipei, Taiwan

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P5-01-21

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P5-01-21

引用

页数：3

共 46 条

[21] Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2-metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update
Damodaran, Senthil
Moore, Halle C. F.
Anderson, Ian Churchill
Cherian, Mathew Amprayil
O'Sullivan, Ciara Catherine
Plourde, Paul V.
Portman, David Jay
Goetz, Matthew P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[22] Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer
Gasch, Christin
Oldopp, Theresa
Mauermann, Oliver
Gorges, Tobias M.
Andreas, Antje
Coith, Cornelia
Mueller, Volkmar
Fehm, Tanja
Janni, Wolfgang
Pantel, Klaus
Riethdorf, Sabine
MOLECULAR ONCOLOGY, 2016, 10 (08): : 1330 - 1343
[23] Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+/HER2-metastatic breast cancer (mBC) in the US
Park, Leah
Thompson, Samantha L.
Roose, James
Lu, Yichen
Chaki, Moumita
Lam, Clara
Iorgulescu, Bryan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] The prevalence of PIK3CA mutations in HR1/HER2-metastatic breast cancer (BELLE2, BELLE3 and BOLERO2 clinical trials)
Wan, K.
Wang, Y. A.
Kaper, M.
Fritzemeier, M.
Babbar, N.
ANNALS OF ONCOLOGY, 2018, 29 : 95 - 95
[25] Characteristics of circulating tumor DNA (ctDNA) in patients with ER-positive (ER1), HER2-negative (HER2-) metastatic breast cancer (MBC) on different lines of endocrine treatment
Bos, M. K.
Kruger, D. T.
Jansen, M. P. H. M.
Martens, J. W. M.
Boven, E.
Sleijfer, S.
ANNALS OF ONCOLOGY, 2019, 30
[26] A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2-breast cancer patients
Dandachi, N.
Graf, R.
Pancheri, L.
Dobric, N.
Klocker, E. V.
Suppan, C.
Jost, P. J.
Heitzer, E.
Balic, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1162 - S1163
[27] Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): Co-occurrence and prevalence along treatment course
Bhave, Manali A.
Quintanilha, Julia
Ross, Jeffrey S.
Graf, Ryon P.
Levy, Mia Alyce
Kalinsky, Kevin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
Takashi Takeshita
Yutaka Yamamoto
Mutsuko Yamamoto-Ibusuki
Mai Tomiguchi
Aiko Sueta
Keiichi Murakami
Hirotaka Iwase
Molecular Cancer, 17
[29] Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA
Dickler, M. N.
Saura, C.
Oliveira, M.
Richards, D. A.
Krop, I. E.
Cervantes, A.
Stout, T. J.
Jin, H.
Savage, H. M.
Wilson, T. R.
Baselga, J.
CANCER RESEARCH, 2017, 77
[30] Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
Takeshita, Takashi
Yamamoto, Yutaka
Yamamoto-Ibusuki, Mutsuko
Tomiguchi, Mai
Sueta, Aiko
Murakami, Keiichi
Iwase, Hirotaka
MOLECULAR CANCER, 2018, 17

← 1 2 3 4 5 →